Segulah Medical Acceleration

About Segulah Medical Acceleration

Segulah Medical Acceleration is the sole Nordic GP fully dedicated to medtech commercialisation with SEK 1.25-1.3 billion (~€110-125 million) of assets under management as of December 2024 (initial commitments c. SEK 1.2 billion), headquartered in Stockholm. The firm was founded in 2021 as an independent medtech specialist established with backing from leading Nordic institutions and prominent private investors. Segulah Medical operates independently from Segulah Advisor (Nordic buyout firm) despite shared Segulah heritage branding.

Investment thesis

Segulah Medical Acceleration deploys capital through one active fund (Segulah Medical Acceleration Fund I) plus co-investment sleeves, targeting medtech-only growth equity that provides early commercialisation capital (SEK 20-150 million ticket / ~€2-15 million) for medtech innovators transitioning from clinical validation to market scale. Sector focus spans medical devices, diagnostics, life science tools, digital health and healthcare technology and surgical and wound care. Geographic deployment is Europe with Nordic emphasis (Sweden, Denmark, Norway, Germany, UK) plus selective US. The medtech-only specialisation combines in-house operating expertise with an external network of medtech-industry veterans accelerating go-to-market.

Recent activity

Recent realised exits include healthcare technology (2024) and diagnostics (2026). Recent acquisitions include a wound care partnership (2024) and diagnostics CEO appointment and build (2024). The platform continues active deployment across the Nordic medtech commercialisation mandate. Detailed buyer names and multiple data available on Pro at €29/month.